India Glycols Limited has informed the Exchange that Board of Directors at its meeting held on May 16, 2025, recommended Final Dividend of 10 per equity share.
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Glycols' Board, at its May 16, 2025 meeting, approved audited standalone and consolidated results for Q4 and FY ended March 31, 2025, with an unmodified auditor's opinion. The Board recommended a final dividend of Rs. 10 per share (100% on face value of Rs. 10), subject to shareholder approval at the AGM. Standalone FY25 revenue grew about 14% to Rs. 9,037.82 crore and profit after tax rose nearly 19% to Rs. 180.38 crore (EPS Rs. 58.26 vs Rs. 49.01). Consolidated FY25 PAT jumped about 33% to Rs. 230.92 crore, helped by a strong share of profit from the Clariant IGL joint venture. Bio-Fuel segment revenue more than doubled year-on-year, while Bio-based Specialities revenue declined. The Board also narrowed its earlier composite scheme of arrangement, deciding to pursue only the demerger of Bio-Pharma and Spirits/Biofuel businesses (appointed date April 1, 2026), dropping the planned amalgamation of Kashipur Holdings.
Shareholders get a healthy 100% dividend alongside a solid year of earnings growth and clean audit opinion, which should be viewed positively. The simplified demerger plan keeps the listed structure cleaner but is a longer-dated event (FY27 onwards) and unlikely to move the stock sharply on its own.